✦ LIBER ✦

Role of disease risk scores in comparative effectiveness research with emerging therapies

✍ Scribed by Robert J. Glynn; Joshua J. Gagne; Sebastian Schneeweiss

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Calendar Time As An Instrumental Variabl

✍ Mack, C.D.; Brookhart, M.A.; Glynn, R.J.; Stürmer, T. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 91 KB

The comparative effectiveness of statin

✍ Xia Sheng, Michael J Murphy, Thomas M MacDonald, Li Wei 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 556 KB

Use of a disease risk score to compare s

✍ Jeffrey R. Curtis; Fenglong Xie; Lang Chen; Paul Muntner; Carlos G. Grijalva; Cl 📂 Article 📅 2012 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 257 KB

OP-138: THE ROLE OF GRACE RISK SCORE IN

✍ B. Akdemir; R.E. Altekin; A. Yanikoglu; M.S. Karakas; S.C. Ozbek; E. Kaya; A. Ak 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 103 KB

Prevalence of Emerging Cardiovascular Ri

✍ Vivek Sailam; Dean G. Karalis; Ashish Agarwal; Firas Alani; Susan Galardi; Veron 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

Using the E-PASS scoring system to estim

✍ Kenichi Koushi; Daisuke Korenaga; Hirofumi Kawanaka; Toshirou Okuyama; Yasuharu 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 147 KB